Salomonsson, S. E.
Maltos, A. M.
Gill, K.
Aladesuyi Arogundade, O.
Brown, K. A.
Sachdev, A.
Sckaff, M.
Lam, K. J. K.
Fisher, I. J.
Chouhan, R. S.
Van Laar, V. S.
Marley, C. B.
McLaughlin, I.
Bankiewicz, K. S.
Tsai, Y.-C.
Conklin, B. R.
Clelland, C. D.
Funding for this research was provided by:
National Institute of Aging (SC-00080)
NIH Common Fund (U19NS132303)
Alzheimer’s Association (AACSF-17-531484)
BrightFocus Foundation (A20201490F)
Target ALS
Article History
Received: 2 August 2023
Accepted: 22 December 2023
First Online: 8 January 2024
Competing interests
: B.R.C. is a founder of Tenaya Therapeutics (ExternalRef removed), a company focused on finding treatments for heart failure, including genetic cardiomyopathies. B.R.C. holds equity in Tenaya. C.D.C. is a founder, with equity, in Ciznor Co., a CNS therapeutics company. I.M and Y-C.T. are full-time employees at Pacific Biosciences (PacBio), a company developing single-molecule sequencing technologies and I.M holds stock in PacBio. K.S.B. is a consultant at Asklepios BioPharmaceutical Inc, Scribe Therapeutics and Aviado Bio. The other authors declare no competing interests.